Crossmark

3462 Safety and efficacy of frexalimab from the phase 2 open-label extension in participants with relapsing multiple sclerosis: 2-year results

Crossref DOI link: https://doi.org/10.1136/bmjno-2025-ANZAN.50

Published Online: 2025-10-23

Published Print: 2025-10

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Vermersch, Patrick

Granziera, Cristina

Mao-Draayer, Yang

Cutter, Gary

Kalbus, Oleksandr

Staikov, Ivan

Dufek, Michal

Montalban, Xavier

Krieger, Stephen

Saubadu, Stephane

Luo, Xiaodong

Smyth, Brendan

Djukic, Biljana

Truffinet, Philippe

Wallstroem, Erik

Giovannoni, Gavin

Simpson, Marion
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04879628 at ClinicalTrials.gov

Documents that mention this clinical trial

3462 Safety and efficacy of frexalimab from the phase 2 open-label extension in participants with relapsing multiple sclerosis: 2-year results
https://doi.org/10.1136/bmjno-2025-anzan.50
License Information

License valid from 2025-10-22